A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates.

about

Successful Kidney Transplantation After Stepwise Desensitization Using Rituximab and Bortezomib in a Highly HLA-Sensitized and ABO Incompatible High Titer Patient

P2860

Q41596280-67015CDC-CA40-4FAE-96F0-C5BE01BCEBAE

P2860

A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates.

Item

http://www.wikidata.org/entity/Q42181436

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@en

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@nl

type

Item

label

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@en

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@nl

prefLabel

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@en

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@nl

P1476

A Phased Desensitization Proto ...... Kidney Transplant Candidates.

@en

P2093

Hideki Ohdan

http://www.w3.org/2001/XMLSchema#string

Hirotaka Tashiro

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Tahara

http://www.w3.org/2001/XMLSchema#string

Kentaro Ide

http://www.w3.org/2001/XMLSchema#string

Kohei Ishiyama

http://www.w3.org/2001/XMLSchema#string

Yu Sasaki

http://www.w3.org/2001/XMLSchema#string

Yuka Tanaka

http://www.w3.org/2001/XMLSchema#string

P2860

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics.

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.

Desensitization in kidney transplantation: review and future perspectives.

Plasma cells in immunopathology: concepts and therapeutic strategies.

Rituximab and immune deficiency: case series and review of the literature.

Early B lymphocyte development: Similarities and differences in human and mouse.

Bortezomib in kidney transplant desensitization: a case report.

Rituximab and intravenous immune globulin for desensitization during renal transplantation.

P304

e17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TXD.0000000000000526

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Masahiro Ohira

P577

2015-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27500219

http://www.w3.org/2001/XMLSchema#string

P932

4946466

http://www.w3.org/2001/XMLSchema#string

A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates.

about

P2860

P2860

A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932